Delcath Systems (DCTH) Scheduled to Post Quarterly Earnings on Friday

Delcath Systems (NASDAQ:DCTH) will release its earnings data before the market opens on Friday, November 8th. Analysts expect Delcath Systems to post earnings of ($0.21) per share for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.

Delcath Systems (NASDAQ:DCTH) last posted its quarterly earnings data on Monday, August 5th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.12). The company had revenue of $7.77 million for the quarter, compared to analysts’ expectations of $5.00 million. Delcath Systems had a negative net margin of 474.22% and a negative return on equity of 312.48%. During the same quarter last year, the business posted ($0.58) EPS. On average, analysts expect Delcath Systems to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Delcath Systems Stock Up 4.2 %

DCTH opened at $10.89 on Friday. The business’s fifty day simple moving average is $9.68 and its 200 day simple moving average is $8.07. Delcath Systems has a 52 week low of $2.25 and a 52 week high of $11.74. The stock has a market cap of $302.59 million, a PE ratio of -4.27 and a beta of 0.78.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on DCTH shares. StockNews.com upgraded Delcath Systems from a “sell” rating to a “hold” rating in a research report on Friday, October 25th. Stephens reiterated a “buy” rating on shares of Delcath Systems in a research report on Friday, October 18th. HC Wainwright restated a “buy” rating and issued a $22.00 price objective on shares of Delcath Systems in a report on Friday, October 18th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $21.00 target price on shares of Delcath Systems in a report on Friday, October 18th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $21.50.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.